Synta Pharmaceuticals Release: Ganetespib Potently Inhibits Multiple Signaling Pathways Active in Breast Cancer
12/12/2011 6:05:05 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium (SABCS). Also reported was an objective response in a patient with metastatic triple-negative breast cancer participating in a ganetespib Phase 1 trial. Additional clinical results for ganetespib in breast cancer were presented on December 7, 2011 at the SABCS showing ganetespib single agent activity in both HER2-positive and triple negative breast cancer.